GENinCode Plc (AIM:GENI)

Market Cap	5.16M
Revenue (ttm)	2.70M
Net Income (ttm)	-4.43M
Shares Out	286.88M
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	374,683
Average Volume	227,111
Open	1.737
Previous Close	1.800
Day's Range	1.600 - 2.000
52-Week Range	1.000 - 8.500
Beta	0.76
RSI	34.00
Earnings Date	Sep 24, 2025

About Heartland Financial USA

GENinCode Plc develops and commercializes clinical genetic tests to provide predictive analysis of risk to a patient’s health based on their genes in the United Kingdom and internationally. Its predictive technology offers patients and physicians with preventative care and treatment strategies. The company’s invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset. Its tests include Cardio inCode, a genetic test to help user to adopt cardiovascular pre...

• Industry: Medical - Diagnostics & Research
• Sector: Healthcare
• Founded: 2018
• Employees: 42
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: GENI

Financial Performance

In 2024, GENinCode's revenue was 2.70 million, an increase of 25.05% compared to the previous year's 2.16 million. Losses were -4.43 million, -36.80% less than in 2023.